GRAIL continues to see momentum after launching the GalleriⓇ test last year as a multi-cancer early detection (MCED) test to be available to patients and providers. Galleri has shown the ability to detect more than 50 types of cancer, most of which have no current screening. We remain very pleased by the market’s reception since launch – with multiple large employers and payers adopting Galleri. To date, Galleri has been prescribed by more than 2,400 prescribing physicians, and GRAIL has entered 34 partnerships with forward-thinking health systems, employers and insurers who are investing in multi-cancer early detection. In the first quarter, we launched Galleri as an employee benefit with several leading companies in the technology, transportation, healthcare, finance, communications and biotechnology sectors. Looking ahead, GRAIL plans to expand its existing sales force for Galleri to reinforce launch traction and drive continued market adoption.
January – April Business Highlights:
- In January, GRAIL announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri. OHSU will provide patients access to Galleri via a pilot program to help find signals of cancer in earlier stages and advance the delivery of cancer care.
- In January, GRAIL announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri. Under the partnership, Premier’s PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test. The alert will be evidence-based, integrated in the workflow and is expected to be compatible with existing electronic medical record systems.
- In February, GRAIL announced an agreement with Point32Health, the combined organization of Harvard Pilgrim Health Care and Tufts Health Plan, to collaborate on a two-phased pilot of Galleri. Point32Health is the first commercial health plan in the U.S. to work with GRAIL on its Galleri multi-cancer early detection test as a complement to recommended cancer screenings.
- GRAIL’s historic, population-scale NHS clinical collaboration continues to progress. The NHS-Galleri trial has enrolled more than 90,000 of the planned 140,000 participants, and depending on the results, could scale to 1 million individuals and eventually nationally. GRAIL expects to review initial results in 2023.
- The COVID pandemic has highlighted the longstanding health inequities in this country and around the globe. Unfortunately, the pandemic also greatly exacerbated existing disparities in cancer care and cancer screening. Given the opportunity we have at GRAIL to dramatically improve public health through multi-cancer early detection, we must prioritize equity in health to ensure that everyone has a fair and just opportunity to prioritize their health. Reflecting our continued commitment to health equity, GRAIL has established a formal Health Equity Program to advance our health equity vision, strategy, goals and related initiatives.
- In April, GRAIL announced its sponsorship of a new PGA Champions Tour golf event, named The GalleriⓇ Classic, to debut in March of 2023 in Rancho Mirage, California at the renowned Mission Hills Country Club. The PGA’s Champions Tour is a renowned circuit with unique touch points to GRAIL’s intended market of people 50 years and older. The Galleri Classic will be the latest addition to the PGA TOUR Champions schedule and net proceeds will benefit cancer-related causes.
- In April, GRAIL signed a multi-year partnership with leading reinsurance provider, Munich Re Life US, to enable access to Galleri as a benefit to policyholders of U.S. life insurance carriers and distributors. The new offering serves as part of Munich Re’s investment in technologies and digital tools to improve the health and wellness of policyholders. Munich Re and GRAIL will work collaboratively to enable carriers and distributors to offer the Galleri test as a value-add service to policyholders who are at elevated risk of cancer, such as those aged 50 or older. Use of the Galleri test will not be used to limit access to life insurance. Munich Re’s significant investment reflects its commitment to helping to advance cancer early detection and treatments that aim to promote healthier and longer lives for policyholders.